Information  X 
Enter a valid email address

Destiny Pharma PLC (DEST)

  Print      Mail a friend

Wednesday 06 November, 2019

Destiny Pharma PLC

Destiny Pharma to present at World AMR Congress

RNS Number : 3690S
Destiny Pharma PLC
06 November 2019
 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Destiny Pharma to present at the World Anti-Microbial Resistance Congress 2019

 

Brighton, United Kingdom - 5 November 2019 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs that address clear commercial opportunities and also address the global problem of anti-microbial resistance (AMR), announces that Neil Clark, Chief Executive Officer of Destiny Pharma, will present on the potential of the Company's XF Drugs to address the threat of AMR at the World Anti-Microbial Resistance Congress on 7-8 November, 2019 in Washington D.C, US.

 

About World Anti-Microbial Resistance Congress

The World Anti-Microbial Resistance Congress has been the only commercially focused conference globally of its kind, since 2015. Launched during the release of key reports such as the AMR Review and a Scientific Roadmap for Antibiotic Discovery, the World AMR Congress has brought attention to the threats of this emerging crisis to the global healthcare system. This AMR focused event attracts 200 speakers and over 600 attendees from over 40 countries.

 

For further information, please contact:

 

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[email protected] 

+44 (0)1273 704 440

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

[email protected] 

+44 (0) 20 3727 1000

 

finnCap Ltd (Nominated Advisor Joint Broker)

Geoff Nash /Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

+44 (0)20 7220 0500

 

WG Partners (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

+44 (0) 203 705 9330

 

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development and commercialisation of novel medicines from its XF Platform that represent a new approach to the treatment of infectious disease. The company's lead programme is undergoing a Phase 2b clinical trial and is targeting the prevention of post-surgical hospital infections including MRSA. The XF drug candidates are being developed for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com

 

About XF-73

XF-73 is a synthetic anti-microbial active against all tested Staphylococcus aureus strains, including drug‑resistant strains. By acting via a cell-surface mechanism it affects the bacterial membrane permeability and integrity, leading to cell death. XF-73 has already been through seven successful Phase I/II clinical trials showing it is safe and delivers a rapid antibacterial action. In standard microbiology studies XF drugs have demonstrated a unique no/low resistance profile that means that XF compounds have the potential to deliver novel drugs that are clearly differentiated from traditional antibiotics where resistance limits their utility.

 

XF-73 is being studies for the prevention of post-surgical staphylococcal infections. In the US, there are approximately 40 million surgeries per annum alone where the patient is at risk of a post-surgical infection. However, within this large population there are particular groups who are at an even higher risk of infection due to the nature of their surgery or the procedures and/or their specific hospital environment in which they are treated. These higher risk surgical procedures include cardiovascular, orthopaedic and other complex surgeries. Destiny Pharma estimates that this totals approximately 14 million US surgeries per year, with this figure set to rise within the context of an ageing population.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAQELFBKFFBFBV

a d v e r t i s e m e n t